Testosterone recovery and changes in bone mineral density after stopping long‐term luteinizing hormone‐releasing hormone analogue therapy in osteoporotic patients with prostate cancer

No abstract is available for this paper.

• Publication year

  2005

• Venue

  BJU International

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-410X.2005.05399.xPMID 15794781
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial

  2005cited by this paper
• Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02

  2004cited by this paper
• EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma.

  2004cited by this paper
• Superficial bladder cancer: state of the art

  2004cited by this paper
• Comorbidity assessment in localized prostate cancer: a review of currently available techniques.

  2004cited by this paper
• The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract

  2003cited by this paper
• Immediate dual energy X‐ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation

  2003cited by this paper
• Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413

  2003cited by this paper
• Endourological management of upper tract transitional cell carcinoma

  2003cited by this paper
• Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

  2002cited by this paper
• Sexuality and Marital Life: Results of a Survey

  2002cited by this paper
• Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma

  2002cited by this paper
• Couples' experiences with prostate cancer: focus group research.

  2002cited by this paper
• Development of a new head and neck cancer-specific comorbidity index.

  2002cited by this paper
• Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.

  2002cited by this paper
• Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma.

  2001cited by this paper
• Altered sexual patterns after treatment for prostate cancer.

  2001cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

  2001cited by this paper
• Beyond Sexual Assessment: Lessons Learned from Couples Post Radical Prostatectomy

  2001cited by this paper
• Communication about prostate cancer between men and their wives.

  2001cited by this paper
• Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?

  2001cited by this paper
• Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

  2001cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  2000cited by this paper
• Association of Hypogonadism and Estradiol Levels with Bone Mineral Density in Elderly Men from the Framingham Study

  2000cited by this paper
• Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?

  2000cited by this paper
• Medical Selection of Life Risks

  2000cited by this paper
• Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancer

  2000cited by this paper
• Psychosocial morbidity in prostate cancer: II. A comparison of patients and partners

  2000cited by this paper
• Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

  2000cited by this paper
• A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.

  2000cited by this paper
• The long‐term outcome after laparoscopic nephroureterectomy: a comparison with open nephroureterectomy

  2000cited by this paper
• The value of a second transurethral resection in evaluating patients with bladder tumors.

  2000cited by this paper
• Endocrine effects, efficacy and tolerability of a 10.8‐mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer

  1999cited by this paper
• MR imaging of the male pelvis

  1999cited by this paper
• Comorbidity in patients with prostate cancer and its relevance to treatment choice

  1999cited by this paper
• Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

  1999cited by this paper
• Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies.

  1999cited by this paper
• Rapid screening for psychologic distress in men with prostate carcinoma

  1998cited by this paper
• A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer

  1998cited by this paper
• Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis.

  1998cited by this paper
• Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer

  1998cited by this paper
• Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.

  1998cited by this paper
• Osteoporosis after orchiectomy for prostate cancer.

  1997cited by this paper
• Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

  1997cited by this paper
• Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma.

  1997cited by this paper
• Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma

  1997cited by this paper
• Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation

  1997cited by this paper
• Interpretation of Kappa and B statistics measures of agreement

  1997cited by this paper
• A Sexual Adjustment Questionnaire for use in therapy and research with alcoholics and their spouses.

  1997cited by this paper
• Routine CT scan in cystectomy patients: does it change management?

  1996cited by this paper
• Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma.

  1996cited by this paper
• A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.

  1996cited by this paper
• The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group".

  1996cited by this paper
• Quality-of-life outcomes in men treated for localized prostate cancer.

  1995cited by this paper
• Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

  1995cited by this paper
• Sexual quality of life in men with prostate cancer

  1995cited by this paper
• [Results of radical cystectomy for bladder cancer].

  1994cited by this paper
• Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

  1994cited by this paper
• Validation of a combined comorbidity index.

  1994cited by this paper
• Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.

  1994cited by this paper
• Self-report assessment of female sexual function: Psychometric evaluation of the brief index of sexual functioning for women

  1994cited by this paper
• Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).

  1993cited by this paper
• Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles.

  1991cited by this paper
• Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.

  1991cited by this paper
• POSSUM: A scoring system for surgical audit

  1991cited by this paper
• Tumors of the upper urinary tract: 10 years of experience.

  1991cited by this paper
• Antidepressants for the Relief of Chronic Pain: Do They Work?

  1989cited by this paper
• Carcinoma of the ureter: a clinicopathologic study of 49 cases.

  1989cited by this paper
• Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation

  1988cited by this paper
• Tumor grade and stage as prognostic variables in upper tract urothelial tumors

  1988cited by this paper
• A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate

  1988cited by this paper
• Primary tumors of the renal pelvis: evaluation of clinical and pathological features in a consecutive series of 10 years.

  1988cited by this paper
• Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.

  1987cited by this paper
• Orchiectomy Versus Long-Acting D-Trp-6-LHRH in Advanced Prostatic Cancer

  1987cited by this paper
• Histopathological review of transitional cell carcinoma of the upper urinary tract.

  1984cited by this paper
• Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia

  1983cited by this paper
• Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'.

  1983cited by this paper
• Management of high grade transitional cell cancer of the upper urinary tract.

  1981cited by this paper
• Primary grade 1 transitional cell carcinoma of the renal pelvis and ureter.

  1980cited by this paper
• Multifactorial index of cardiac risk in noncardiac surgical procedures.

  1977cited by this paper
• Measuring Dyadic Adjustment: new scales for assessing the quality of marriage and similar dyads

  1976cited by this paper
• The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus.

  1974cited by this paper
• Profile of mood states

  1971cited by this paper
• CUMULATIVE ILLNESS RATING SCALE

  1968cited by this paper
• Infiltrating carcinoma of the bladder; relation of depth of penetration of the bladder wall to incidence of local extension and metastases.

  1946cited by this paper

• Association Between Rectal Spacer Use and Erectile Dysfunction Diagnosis Among Men Receiving Prostate Radiotherapy: US County‐Level Analysis

  2025cites this paper
• Effect of androgen deprivation therapy on bone mineral density in patients with prostate cancer

  2022cites this paper
• Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study

  2017cites this paper
• Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.

  2015cites this paper
• Bone Mineral Density in Prostate Cancer Patients with Drug Induced Hypogonadism

  2014influential citation
• Molecular Biology and Prostate Cancer

  2013cites this paper
• Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer

  2010cites this paper
• Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

  2008cites this paper
• Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality‐of‐life issues

  2007cites this paper
• Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

  2006cites this paper
• Author index

  2005cites this paper